Table 2 Baseline Characteristics of Sample: Overall and by Anticholinergic Usea (n = 61,451)
Overall | User of AC | Non-use of AC | ||||
|---|---|---|---|---|---|---|
(n = 61,451) | (n = 6940) | (n = 54,511) | ||||
N | % | N | % | N | % | |
Age group at screening | ||||||
65–69 | 31,008 | 50.5 | 3427 | 49.4 | 27,581 | 50.6 |
70–74 | 21,491 | 35.0 | 2486 | 35.8 | 19,005 | 34.9 |
75+ | 8952 | 14.6 | 1027 | 14.8 | 7925 | 14.5 |
Race/ethnicity | ||||||
White | 54,015 | 87.9 | 6264 | 90.3 | 47,751 | 87.6 |
Black | 3572 | 5.8 | 314 | 4.5 | 3258 | 6.0 |
Hispanic | 1241 | 2.0 | 160 | 2.3 | 1081 | 2.0 |
American Indian | 200 | 0.3 | 34 | 0.5 | 166 | 0.3 |
Asian/Pacific Islander | 1594 | 2.6 | 82 | 1.2 | 1512 | 2.8 |
Unknown | 829 | 1.4 | 86 | 1.2 | 743 | 1.4 |
Number of falls in last 12 months (missing = 1658) | ||||||
None | 40,419 | 67.6 | 4194 | 61.8 | 36,225 | 68.3 |
1 | 12,200 | 20.4 | 1442 | 21.3 | 10,758 | 20.3 |
2 | 4946 | 8.3 | 734 | 10.8 | 4212 | 8.0 |
3 or more | 2228 | 3.7 | 415 | 6.1 | 1813 | 3.4 |
Fair or poor self-reported health | 5426 | 8.8 | 1049 | 15.1 | 4377 | 8.0 |
Smoking status (missing = 698) | ||||||
Never | 32,298 | 53.2 | 3486 | 51.0 | 28,812 | 53.4 |
Past | 25,459 | 41.9 | 3017 | 44.1 | 22,442 | 41.6 |
Current | 2996 | 4.9 | 337 | 4.9 | 2659 | 4.9 |
Minutes per week spent walking (missing = 137) | ||||||
0 min | 19,045 | 31.1 | 2494 | 36.0 | 16,551 | 30.4 |
>0–150 min | 32,225 | 52.6 | 3529 | 51.0 | 28,696 | 52.8 |
>150 min | 10,044 | 16.4 | 903 | 13.0 | 9141 | 16.8 |
Alcohol intake | ||||||
Non drinker | 7375 | 12.0 | 852 | 12.3 | 6523 | 12.0 |
Past drinker | 11,657 | 19.0 | 1615 | 23.3 | 10,042 | 18.4 |
<7 drinks per week | 34,646 | 56.4 | 3665 | 52.8 | 30,981 | 56.8 |
7+ drinks per week | 7773 | 12.7 | 808 | 11.6 | 6965 | 12.8 |
BMI (kg/m2) | ||||||
Underweight (<18.5) | 619 | 1.0 | 58 | 0.8 | 561 | 1.0 |
Normal (18.5–24.9) | 21,919 | 35.7 | 2184 | 31.5 | 19,735 | 36.2 |
Overweight (25.0–29.9) | 22,341 | 36.4 | 2601 | 37.5 | 19,740 | 36.2 |
Obese (≥30.0) | 16,572 | 27.0 | 2097 | 30.2 | 14,475 | 26.6 |
Rand Physical Function score >90 (missing = 731) | 16,870 | 27.8 | 1191 | 17.4 | 15,679 | 29.1 |
Urinary incontinence | 19,244 | 31.3 | 2754 | 39.7 | 16,490 | 30.3 |
History of Parkinson’s disease | 228 | 0.4 | 64 | 0.9 | 164 | 0.3 |
Insomnia Rating Scale | ||||||
0–3 | 15,317 | 24.9 | 1296 | 18.7 | 14,021 | 25.7 |
4–6 | 17,171 | 27.9 | 1698 | 24.5 | 15,473 | 28.4 |
7–10 | 16,493 | 26.8 | 2034 | 29.3 | 14,459 | 26.5 |
≥11 | 12,470 | 20.3 | 1912 | 27.6 | 10,558 | 19.4 |
Depression (Burnham score >0.06) | 5230 | 8.5 | 941 | 13.6 | 4289 | 7.9 |
Treated diabetes (oral or insulin) | 2962 | 4.8 | 454 | 6.5 | 2508 | 4.6 |
Alzheimer Disease | 35 | 0.1 | 2 | 0.03 | 33 | 0.1 |
Arthritis | 34,728 | 56.5 | 4746 | 68.4 | 29,982 | 55.0 |
Anti-epileptic use | 605 | 1.0 | 152 | 2.2 | 453 | 0.8 |
Benzodiazepine receptor agonist use | 2563 | 4.2 | 860 | 12.4 | 1703 | 3.1 |
Antidepressant use | 1710 | 2.8 | 409 | 5.9 | 1301 | 2.4 |
Antipsychotic use | 54 | 0.1 | 27 | 0.4 | 27 | 0.1 |
Number of psychoactive meds | ||||||
0 | 57,378 | 93.4 | 5723 | 82.5 | 51,655 | 94.8 |
1 | 3666 | 6.0 | 1072 | 15.5 | 2594 | 4.8 |
2+ | 407 | 0.7 | 145 | 2.1 | 262 | 0.5 |
Dizziness (moderate/severe) (missing = 156) | 1829 | 3.0 | 412 | 6.0 | 1417 | 2.6 |
Low back pain (moderate/severe) | 12,719 | 20.7 | 2160 | 31.1 | 10,559 | 19.4 |
Vision problem uncorrected (moderate/severe) | 3560 | 5.8 | 550 | 7.9 | 3010 | 5.5 |
WHI Participation | ||||||
Hormone therapy trial | 10,986 | 17.9 | 1180 | 17.0 | 9806 | 18.0 |
Diet modification trial | 16,497 | 26.9 | 1754 | 25.3 | 14,743 | 27.1 |
Calcium vitamin D trial | 12,706 | 20.7 | 1272 | 18.3 | 11,434 | 21.0 |
Observational study | 36,723 | 59.8 | 4288 | 61.8 | 32,435 | 59.5 |